Aronora

Aronora is proud to share that we presented new data on AB023 and AB062 at hashtag .

AB023 is a first-in-class, Factor XI (FXI) inhibitor designed to bind the Apple 2 (A2) domain of FXI. This differentiated mechanism of action selectively inhibits Factor XII–mediated contact activation of FXI, while preserving thrombin-mediated FXI activation that supports fully functional hemostasis.

AB062 is a first-in-class, antisense oligonucleotide designed to inhibit hepatic production of thrombopoietin – a key regulator of platelet production whose signaling pathway is aberrantly activated in myeloproliferative neoplasms like essential thrombocythemia (ET).

We’re excited to hear KOLs echo our belief in the potential for Aronora's first-in-class programs to better serve patient communities at risk for life-threatening thrombosis.

Thank you to the hashtag organizers for an engaging program and we look forward to a productive year ahead!

“The venture arm is also a way for NYBC to apply its experience and capital to advance technologies for underserved areas of medicine…it is finalizing a deal to invest $2m in Aronora. A company developing drugs for blood diseases…generally raising venture capital in this field is difficult because of the perception that startups would need giant clinical studies to prove their drugs are effective in a range of patients who need anti clotting therapies…a startup can break into the market by targeting a narrower slice of the broad population… Aronora is developing its lead drug in patients on dialysis who can’t tolerate blood thinners…”

New Venture Fund Targets Innovations in Blood Research New York Blood Center and other healthcare nonprofits are using venture capital to help startups tackle diseases.

Out website got a facelift. :) www.aronorabio.com

Home PARADIGM SHIFTING DRUGS FOR LIFE-THREATENING BLOOD DISEASES PARADIGM SHIFTING DRUGS FOR BLOOD DISEASES FIRST-IN-CLASS SAFE BIOLOGIC DRUGS Aronora is committed to developing and commercializing safe, first-in-class medicines for blood diseases with significant unmet medical need. MORE ABOUT US FIRST-...

We love our new home! Thank you SmithArnold Inc.

“The problem we are having is that while we understand that there is a clot, we don’t yet understand why there is a clot,” Kaplan said. “We don’t know. And therefore, we are scared.”

A mysterious blood-clotting complication is killing coronavirus patients Once thought to be a relatively straightforward respiratory virus, covid-19 is proving to be much more complex and frightening

Dr. Thomas Oxley, a neurosurgeon at Mount Sinai Health System in New York, and colleagues gave details of five people they treated. All were under the age of 50, and all had either mild symptoms of Covid-19 infection or no symptoms at all.
"The virus seems to be causing increased clotting in the large arteries, leading to severe stroke," Oxley told CNN.

Covid-19 causes sudden strokes in young adults, doctors say The new coronavirus appears to be causing sudden strokes in adults in their 30s and 40s who are not otherwise terribly ill, doctors reported Wednesday.

The Contact Activation System as a Potential Therapeutic Target in Patients with COVID‐19 https://onlinelibrary.wiley.com/doi/10.1002/rth2.12349

Not all strokes look the same...

She Felt Fine, but Her M.R.I. Showed Several Strokes. What Was Wrong? After the 67-year-old woman fell at the airport, the left side of her body wouldn’t cooperate. The answer to her malady was found in her heart.

Interesting.

Bacteria-infected mosquitoes take bite out of deadly dengue WASHINGTON (AP) — They still bite, but new research shows lab-grown mosquitoes are fighting dangerous dengue fever that they normally would spread. Dengue infections appear to be dropping...

A nice mention for us in Willamette Week and an assessment of the startup climate in Portland Oregon, the 21st most entrepreneurial city, a 10-rank increase from the previous year and one of the largest year-by-year increases according a Kauffman Foundation study.

Is Oregon Home to the Next Billion-Dollar Company? This spring, Oregon almost saw its first unicorn. A “unicorn” is a company that sells for $1 billion. In May, an Oregon company almost did just that: Cura Cannabis was acquired by a Canadian company for $949 million in stock.

Thanks for the shout out BioSpace ! Aronora is proud to be a part of the Oregon life science community.

Oregon’s Biopharma Market Heats Up | BioSpace The Oregon Bioscience Association recently released a new economic impact report, showing that the state’s biopharma and life science industry is continuing to grow at a significant clip.